gsk

TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.

GSK subsidiary, TESARO, Inc., confirms it has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court. This action contends that recent conduct by AnaptysBio is in material breach ...
gsk

GSK makes strong start to 2025 with growth in sales, profits and earnings

Data presented at CROI for VH184, VH499 and N6LS support development plans for ULA HIV regimens Breakthrough designation granted for GSK'227 B7H3 ADC for 2L osteosarcoma Pivotal/Phase III trials ...
gsk

European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time In Europe, RSV leads to over 270,000 hospitalisations and approximately ...
gsk

Roy Jakobs to join GSK Board as Non-Executive Director

GSK plc (LSE/NYSE: GSK) has today announced that Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026. Mr Jakobs is currently Chief Executive Officer of Royal ...
gsk

GSK and Flagship Pioneering partner to discover novel medicines and vaccines

Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies Initial phase to identify and accelerate promising scientific ...
gsk

GSK delivers strong Q3 performance and continued momentum

Total Q3 sales £8.9 billion +4% AER; +5% CER Specialty Medicines sales £3.9 billion (+15%); HIV sales £2.1 billion (+10%), Respiratory, Immunology & Inflammation £1.1 billion (+21%); Oncology £0.6 ...
gsk

ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at ...

Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...
gsk

GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial

GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of the TH HSV REC-003 trial. This trial is a combined phase I/II ...
gsk

For media and investors only

GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, ...
gsk

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III ...
gsk

Ris-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China

GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd., today announced positive results from its ARTEMIS-011 study, a pivotal phase III trial in China evaluating risvutatug rezetecan ...
gsk

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

GSK plc (LSE/NYSE: GSK) today announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate (ADC). Results ...